Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Apr 2024 – Dec 2024Where it's discussed
-
X / Twitter53 posts
-
News12 articles
-
YouTube9 videos
-
Blogs3 articles
AI synopsis
What people are saying
Overall, the social discussions demonstrate strong support and interest, with examples like congratulatory messages for the authors and references to how the study offers promising new approaches. The tone of enthusiasm and emphasis on the research's significance reflect its perceived high impact in the field.
Most discussions express support for the research, highlighting its importance in treating TP53-mutant cancers.
Many posts show high interest, referencing the article’s potential to advance therapies and its scientific significance.
Posts include congratulations to co-authors and references to the publication, indicating active engagement.
The discussions suggest the research is seen as impactful, with mentions of 'promising' and 'significant' advances in cancer treatment.
Abstract in brief
- The article discusses how BH3mimetic drugs, which induce apoptosis in blood cancer cells, require functional p53 for maximum effectiveness, but in TP53-deficient cancers, this pathway is compromised, leading to potential treatment failure.
- It explains that p53 activation occurs after mitochondrial permeabilization caused by BH3mimetics, which then increases BH3-only proteins to enhance cell death; however, TP53-deficient cancers lack this feedback loop.
- The researchers found that activating the cGAS-STING pathway can bypass the need for p53 by upregulating BH3-only proteins, and combining STING agonists with BH3mimetics effectively kills TP53-mutant blood cancer cells, offering a promising new therapy approach.]
Top posts
Most liked on X and BlueskyOnline Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.co/4WMhwhxQ2L
BAK/BAXが活性化されミトコンドリアの膜透過性が上昇(MOMP)=アポトーシスと思ってたけど、さらにMOMPがTP53を活性化するフィードバックが重要で、TP53変異のある腫瘍で(文字数) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers: Cancer Cell https://t.co/o5jQeIGQkB
Putting the #STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2hmXws2GjZ @Kiran_Batta https://t.co/NW7TrUaNK5
The LDCRC wishes to congratulate @RossAisling who is listed as a co-author on the paper Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. The full paper can be found here - https://t.co/sVsN5dGfcG #ldcrc #ul #cancerresearch
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
All mentions
cGAS/STING Pathway as an Alternative in p53 Mutant Blood Cancers
The cGAS-STING pathway can bypass p53 deficiencies in blood cancer cells, enhancing apoptosis. This approach offers a promising new therapy for TP53-mutant cancers by activating immune signaling to promote cell death.
Enhancing Blood Cancer Therapy with STING Activation and BH3 Mimetics
This video explores how activating the cGAS-STING pathway can bypass p53 deficiencies to induce apoptosis in blood cancer cells using BH3 mimetics, highlighting a promising combined therapeutic approach.
cGAS/STING Activation Induces BH-3 Genes in p53-Deficient Blood Cancers
This video explains how activating the cGAS-STING pathway can upregulate BH-3 proteins to induce apoptosis in blood cancers lacking functional p53, providing potential for improved therapies when traditional BH3-mimetic…
Enhancing Blood Cancer Treatment with STING and BH3 mimetics
This video explores how activating the cGAS-STING pathway can boost apoptosis in TP53-mutant blood cancers by upregulating BH3-only proteins, offering a promising combination therapy with BH3 mimetics.
Combining STING Agonists and BH3 Mimetics to Treat TP53-Mutant Blood Cancers
This video discusses how BH3mimetic drugs induce apoptosis in blood cancer cells and how activating the cGAS-STING pathway can overcome p53 deficiencies by upregulating proapoptotic proteins, offering a promising new…
Enhancing Blood Cancer Therapy with STING and BH3 Mimetics
This video explores how activating the cGAS-STING pathway alongside BH3 mimetics can bypass p53 dependence, effectively inducing apoptosis in TP53-mutant blood cancers and offering potential new treatment strategies.
Combining STING Agonists and BH3 Mimetics to Treat TP53-Mutant Blood Cancers
This video discusses how activating the cGAS-STING pathway can bypass the need for p53 in blood cancer therapy, enhancing the effectiveness of BH3 mimetics in TP53-deficient cancers, and offering new treatment prospects.
Enhancing BH3-Mimetics in TP53-Mutant Blood Cancers via STING Activation
The video discusses how inhibiting BH-2 proteins triggers mitochondrial outer membrane permeabilization, activating p53. It highlights the potential of combining STING pathway activators with BH3-mimetics to improve…
Enhancing Blood Cancer Treatment by Combining STING Activation with BH3 Mimetics
This video discusses how activating the cGAS-STING pathway can improve the effectiveness of BH3 mimetic drugs in treating TP53-mutant blood cancers, offering a potential new therapy approach for tumors lacking…
RT @LDCRC_UL: The LDCRC wishes to congratulate @RossAisling who is listed as a co-author on the paper Putting the STING back into BH3-mimet…
The LDCRC wishes to congratulate @RossAisling who is listed as a co-author on the paper Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. The full paper can be found here - https://t.co/sVsN5dGfcG #ldcrc #ul #cancerresearch
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
RT @Cancer_Cell: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2Sstuyof4q https://t.co/yWvQ4XjDD0
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers - ScienceDirect https://t.co/Zhf4JA6vZH
RT @masayuki_umeda_: BAK/BAXが活性化されミトコンドリアの膜透過性が上昇(MOMP)=アポトーシスと思ってたけど、さらにMOMPがTP53を活性化するフィードバックが重要で、TP53変異のある腫瘍で(文字数) Putting the STING ba…
BAK/BAXが活性化されミトコンドリアの膜透過性が上昇(MOMP)=アポトーシスと思ってたけど、さらにMOMPがTP53を活性化するフィードバックが重要で、TP53変異のある腫瘍で(文字数) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers: Cancer Cell https://t.co/o5jQeIGQkB
Trend up+160: Diepstraten ST, ..., Kelly GL (Cancer Cell) __Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers__ https://t.co/yVoBGl0CWw
RT @Wang_Yu_Hung: Putting the #STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2hmXws2GjZ @Kiran_Batta https:/…
RT @Wang_Yu_Hung: Putting the #STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2hmXws2GjZ @Kiran_Batta https:/…
Putting the #STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/2hmXws2GjZ @Kiran_Batta https://t.co/NW7TrUaNK5
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers #science #publication #research #publications https://t.co/XW8zI24Q5C
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
RT @Cancer_Cell: Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.…
Online Now: Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers https://t.co/4jzOpJq8cg https://t.co/4WMhwhxQ2L
EK